Routemaps for Highly Effective Tuberculosis Vaccination

Maike Assmann; Katrin D Mayer-Barber

doi:10.1016/j.immuni.2020.01.017

Routemaps for Highly Effective Tuberculosis Vaccination

Immunity. 2020 Feb 18;52(2):219-221. doi: 10.1016/j.immuni.2020.01.017.

Authors

Maike Assmann¹, Katrin D Mayer-Barber²

Affiliations

¹ Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
² Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: mayerk@niaid.nih.gov.

Abstract

There is no highly effective tuberculosis vaccine. Darrah et al. (2020) and Tait et al. (2019) are setting new benchmarks for protection against infection and pulmonary disease by changing the route of vaccine delivery and by using a protein subunit vaccine with a potent adjuvant.

Published by Elsevier Inc.

Publication types

Research Support, N.I.H., Intramural
Comment

MeSH terms

Humans
Mycobacterium tuberculosis / immunology*
Tuberculosis Vaccines*
Tuberculosis*
Vaccination
Vaccines, Subunit

Substances

Tuberculosis Vaccines
Vaccines, Subunit

Abstract

Publication types

MeSH terms

Substances

Grants and funding